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Lysine-specific demethylase 1 (LSD1) exerts path-
way-specific activity in animal development and
has been linked to several high-risk cancers. Here,
we report that LSD1 is an integral component of
the Mi-2/nucleosome remodeling and deacetylase
(NuRD) complex. Transcriptional target analysis re-
vealed that the LSD1/NuRD complexes regulate
several cellular signaling pathways including TGFb1
signaling pathway that are critically involved in cell
proliferation, survival, andepithelial-to-mesenchymal
transition. We demonstrated that LSD1 inhibits the
invasionofbreast cancercells in vitroandsuppresses
breast cancer metastatic potential in vivo. We found
that LSD1 is downregulated in breast carcinomas
and that its level of expression isnegativelycorrelated
with that of TGFb1. Our data provide a molecular
basis for the interplay of histone demethylation and
deacetylation in chromatin remodeling. By enlisting
LSD1, the NuRD complex expands its chromatin re-
modeling capacity to includeATPase, histone deace-
tylase, and histone demethylase.
INTRODUCTION
Lysine specific demethylase 1 (LSD1/BHC110/KIAA0601/
p110b/AOF2/KDM1) is an amine oxidase that catalyzes histone
demethylation via a flavin adenine dinucleotide (FAD)-dependent
oxidative reaction (Lan et al., 2008; Shi et al., 2004). Biochemi-
cally, LSD1 acts to remove the mono- and di-methyl moieties
from H3-K4 and, functionally, LSD1 impacts on the chromatin
configuration governing transcription regulation. To date, LSD1
has been identified in a number of corepressor complexes
including CoREST (Lee et al., 2005; Shi et al., 2005), CtBP
(Wang et al., 2007b) and a subset of HDAC complexes (You
et al., 2001), and it has also been shown to interact with p53,
repress p53-mediated transcription and inhibit p53-promoted
apoptosis (Huang et al., 2007).660 Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc.Despite progress in understanding the dynamic histone-
methylation regulation and in revealing the diverse molecular
interactions for LSD1, the biological function of LSD1 is just
beginning to be uncovered. Although the histone demethyla-
tion/transcription regulation activity of LSD1 is potentially wide-
spread, evidence suggests that LSD1 nevertheless performs
pathway-specific functions (Di Stefano et al., 2007; Shi, 2007).
In addition, recent studies have implicated LSD1 in several
growth-promoting pathways and have linked LSD1 to certain
high-risk tumors (Forneris et al., 2008; Kahl et al., 2006; Shi,
2007; Wang et al., 2007a). Indeed, within the framework of the
so-called epigenetic therapies, there is a growing interest in
LSD1 as a potential drug target (Shi, 2007).
Here we propose that LSD1 is an integral component of the
Mi-2/nucleosome remodeling and deacetylase (NuRD) complex,
adding histone demethylation activity to this complex. We show
that LSD1/NuRD complexes regulate the metastatic potential of
breast cancer cells and suppress breast cancer metastasis,
implicating LSD1 in breast cancer metastasis.
RESULTS
LSD1 Is an Integral Component of the NuRD Complex
Molecular carcinogenesis has been the primary research focus
in this laboratory (Shang, 2006; Shang and Brown, 2002; Shang
et al., 2000; Shi et al., 2007;Wu et al., 2005; Yin et al., 2004). In an
effort to better understand the mechanistic roles of the metas-
tasis tumor antigen (MTA), a subunit of the NuRD complex
(Bowen et al., 2004; Denslow and Wade, 2007; Fujita et al.,
2003; Kumar et al., 2003), in cancer metastasis, we employed
affinity purification and mass spectrometry to identify the
proteins that are associated with MTA2, the phylogenetically
closest relative to the ancestral MTA protein (Denslow and
Wade, 2007;Manavathi and Kumar, 2007). In these experiments,
FLAG-tagged MTA2 (FLAG-MTA2) was stably expressed in
HeLa cells. Cellular extracts were prepared and subjected to
affinity purification using an anti-FLAG affinity gel. Mass spectro-
metric analysis indicate that MTA2 copurified with Mi-2, HDAC1,
HDAC2, RbAp46, RbAp48, and MBD3, all of which are compo-
nents of the NuRD complex, as well as with LSD1 (Figure 1A).
In addition, BRCA2 was also detected in the complex. The pres-
ence of LSD1 in the MTA2/NuRD complex was further confirmed
with its antibodies by western blotting analysis (Figure 1B), sug-
gesting that LSD1 is associated with the NuRD complex in vivo.
The detailed results of the mass spectrometric analysis are
provided in the Supplemental Data available with this article
online.
Figure 1. LSD1 Is Associatedwith the NuRD
Complex
(A) Immunoaffinity purification of MTA2-containing
protein complexes. Cellular extracts from HeLa
cells stably expressing FLAG (control) or FLAG-
MTA2were immunopurified with anti-FLAG affinity
columns and eluted with FLAG peptide. The
eluates were resolved by SDS-PAGE and silver-
stained. The proteins bands were retrieved and
analyzed by mass spectrometry. Detailed results
from themass spectrometric analysis are provided
in the Supplemental Data.
(B) Western blotting analysis of the identified
proteins in the purified fractions using antibodies
against the indicated proteins.
(C) Cofractionation of LSD1 and the NuRD
complex by FPLC. Cellular extracts from HeLa
cells were fractionated on Superose 6 size exclu-
sion columns. Chromatographic elution profiles
and immunoblotting analysis of the chromato-
graphic fractions are shown. The elution positions
of calibration proteins with known molecular
masses (kDa) are indicated, and an equal volume
from each fraction was analyzed.
To further show that LSD1 is associated
with the NuRD complex in vivo, protein
fractionation experiments were carried
out by fast protein liquid chromatography
(FPLC) with Superose 6 columns and
a high salt extraction and size exclusion
approach. Native LSD1 from HeLa cells
was eluted with an apparent molecular
mass much greater than that of the
monomeric protein; LSD1 immunoreac-
tivity was detected in chromatographic
fractions from the Superose 6 column
with a relatively symmetrical peak cen-
tered between669 and1000 kDa (Fig-
ure 1C). Significantly, the elution pattern
of LSD1 largely overlapped with that of
the NuRD complex proteins including
MTA2, HDAC1, HDAC2, and RbAp46/
48, further supporting the idea that LSD1
is associated with the NuRD complex
in vivo. Moreover, the chromatographic
profiles of the NuRD complex and LSD1
were compatible with their associated
enzymatic activities. Specifically, histone
deacetylation activity as well as histone
demethylation activity was detected
when the corresponding chromato-
graphic fractions were incubated with
calf thymus bulk histones and analyzed
by western blotting with antibodies against acetyl-H3 and
dimethyl-H3K4, respectively (Figure 1C, bottom three panels).
Interestingly, the chromatographic profile of LSD1was also over-
lapped with that of CoREST, suggesting that LSD1/NuRD
complex and LSD1/CoREST complex coexist in HeLa cells.Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc. 661
To confirm the in vivo interaction between LSD1 and the NuRD
complex, total proteins from HeLa cells were extracted, and
coimmunoprecipitation experiments were performed with anti-
bodies detecting the endogenous proteins. Immunoprecipitation
(IP)with antibodies against LSD1 followedby immunoblotting (IB)
with antibodies against Mi-2, HDAC1, HDAC2, MBD3, MTA1,
MTA2, or MTA3 demonstrated that LSD1 coimmunoprecipitated
with all of the NuRD components (Figure 2A, first column). Recip-
rocally, IP with antibodies against the components of the NuRD
complex and IB with antibodies against LSD1 also revealed
that the components of the NuRD complex coimmunoprecipi-
tated with LSD1 (Figure 2A, second column). In addition, the
association between LSD1 and the NuRD complex was also
detected in humanbreast carcinomaMCF-7 cells (Figure 2B, first
column) and MDA-MB-231 cells (Figure 2B, second column)
when corresponding cellular extracts were immunoprecipitated
with antibodies against LSD1 followed by immunoblotting with
antibodies against Mi-2, HDAC1, HDAC2, MBD3, MTA1, MTA2,
or MTA3.
To determine the relative amount of LSD1 associated with
the NuRD complex versus that associated with CoREST in
HeLa cells, equal amounts of HeLa cellular extracts were coim-
munoprecipitated with antibodies against Mi-2 and CoREST,
respectively. Immunoprecipitates were then immunoblotted
with anti-LSD1. It is estimated that amount of LSD1 associated
with the NuRD versus that associated with CoREST complex is
5:3 in HeLa cells (Figure 2C).
MTA2-Containing Complex Possesses Both Histone
Demethylation and Deacetylation Activities
To further investigate the physical association and to examine
the functional connection between LSD1 and the NuRD
complex, the MTA2-containing protein complex was immuno-
precipitated from HeLa cells stably expressing FLAG-MTA2
with the anti-FLAG antibody and analyzed for enzymatic activi-
ties. The immunoprecipitates (IPs) were first incubated either
with bulk histones (Figure 3A) or with mononucleosomes
(Figure 3B) isolated fromHeLa cells, and the levels of methylated
and acetylated histones in the reactions were then analyzed by
western blotting. As expected, the MTA2-containing complex
possessed an enzymatic activity that led to a significant
decrease in the acetylation level of H3. Remarkably, however,
the immunoprecipitates also contained a strong demethylase
activity for di-methyl H3-K4 and an evident demethylase activity
for mono-methyl H3-K4 on both bulk histones and the nucleo-
somal substrates, whereas no apparent effect on the di-methyl
of H3-K9 was detected. Furthermore, the demethylation activity
of the immunoprecipitates on di-methyl H3-K4 could be effec-
tively inhibited by pargyline, an inhibitor specific for monoamine
oxidases such as LSD1 (Figure 3C).
In vitro deacetylation and demethylation assays were also per-
formed by incubating the immunoprecipitates with [3H]methyl-
labeled histone substrates or [3H]acetate-labeled HeLa histones.
The deacetylation and demethylation activity of the immunopre-
cipitates were measured by quantifying the release of radiola-
beledacetyl groupsor the formationof [3H]-labeled formaldehyde
from hyperacetylated HeLa histones or purified hypermethylated
histone substrates, respectively. We found that the immuno-662 Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc.precipitates had histone deacetylation activity that could be
effectively inhibited by trichostatin A (TSA), an HDAC inhibitor
(Figure 3D, left). Additionally, the MTA2-containing complex
also exhibited histone demethylase activity which could be effec-
tively inhibited by pargyline (Figure 3D, right). Together with the
Figure 2. Physical Interaction between LSD1 and theNuRDComplex
(A) Association of LSD1 with the NuRD complex in HeLa cells. Whole cell
lysates were immunoprecipitated (IP) with the antibodies against the indicated
proteins. Immunocomplexes were then immunoblotted (IB) using antibodies
against the indicated proteins.
(B) Association of LSD1 with the NuRD complex in MCF-7 and MDA-MB-231
cells.
(C) Equal amounts of HeLa cellular extracts were coimmunoprecipitated with
antibodies against Mi-2 or CoREST, respectively. Immunoprecipitates were
then immunoblotted with anti-LSD1.
Figure 3. Functional Connection between LSD1 and the NuRD
Complex
(A) The MTA2-containing protein complex possesses both histone demethyla-
tion and histone deacetylation activities. Cellular extracts were obtained from
HeLa cells stably expressing FLAG-MTA2 and were immunoprecipitated with
anti-FLAG antibody. The immunoprecipitates (IPs) were incubated with bulk
histones and histone demethylation (HDM) or histone deacetylation (HDAC)
assay buffer. The reaction mixtures were analyzed by western blotting using
antibodies against the indicated histone marks or proteins. Acetyl-H3 repre-
sents acetyl-K9/K14 H3.
(B) The MTA2-containing protein complex can recognize nucleosomal
substrates. Above-described IPs were incubated with mononucleosomes
(Nucs) isolated from HeLa cells. The reaction mixtures were analyzed by
western blotting using antibodies against the indicated histone marks or
proteins.enzymatic activity measurements conducted in fractionation
experiments, these data indicate that the MTA2-containing
complex possesses both histone deacetylation and demethyla-
tion activities.
In order to further support the idea that the demethylation
activity and the deacetylation activity of the MTA2-containing
complex are indeed physically associated, we performed immu-
nodepletion assays in which the immunoprecipitates were incu-
bated with anti-LSD1- or anti-MTA2-conjugated protein A/G-
Sepharose beads. After two rounds of incubation and the
removal of the resins by centrifugation, the supernatants were
then used to perform deacetylase and demethylase assays
with [3H]-labeled HeLa cell histones or histone substrates.
Immunodepletion of LSD1 resulted in a drastic decrease in the
deacetylation activity (Figure 3E, upper left) and immunodeple-
tion of MTA2 led to a significant loss in the demethylation activity
of the MTA2-containing protein complex (Figure 3E, upper right).
As control, LSD1-immunodepletionwas associatedwith a dimin-
ished demethylation activity (Figure 3E, lower left) and MTA2-
immunodepletion was accompanied by a decreased deacetyla-
tion activity (Figure 3E, lower right). These experiments strongly
indicate that LSD1 and the NuRD complex are both physically
and functionally associated, further supporting the idea that
LSD1 is a subunit of the NuRD complex. The efficiency of the
immunodepletion was examined by western blotting analysis
of the supernatants (Figure 3E).
LSD1 Interacts Directly with MTA Proteins
In order to determine the molecular basis for the interaction of
LSD1 with the NuRD complex, GST pull-down assays were con-
ducted using GST-fused LSD1 construct and in vitro tran-
scribed/translated individual components of the NuRD complex
including MTA1, MTA2, MTA3, HDAC1, HDAC2, RbAp46, and
RbAp48. These experiments revealed that LSD1 interacts
directly with MTA1, MTA2 and MTA3, but not with the other
components of the NuRD complex that we tested (Figure 4A).
LSD1 is an asymmetric molecule consisting of several distinct
structural domains: the N-terminal putative nuclear localization
signal followed by the SWIRM (Swi3, Rsc8, and Moira) domain;
in the C terminus, there is a Tower domain that protrudes as
an elongated helix-turn-helix motif out of the FAD-binding amine
oxidase domain (AOD) (Cheng and Zhang, 2007; Forneris et al.,
(C) The histone demethylation activity of the MTA2-containing complex could
be inhibited by pargyline. A similar experimental procedure as described for
Figure 3A was followed with the addition of 1 mM of pargyline in the reactions.
(D) Histone demethylation and histone deacetylation activities of the MTA2-
containing complex assayed with [3H]acetate-labeled HeLa histones or
[3H]methyl-labeled histone substrates. The deacetylation and demethylation
activities were measured by quantifying the release of radiolabeled acetyl
groups or the formation of [3H]-labeled formaldehyde, respectively, using
liquid scintillation counting. Each bar represents the mean ± SD for triplicate
measurements. cpm: counts per minute.
(E) Histone deacetylation and demethylation activities of the MTA2-containing
complex assayed with [3H]acetate-labeled HeLa histones or [3H]methyl-
labeled histone substrates after immunodepletion with antibodies against
LSD1 or MTA2. Each bar represents the mean ± SD for triplicate measure-
ments. The efficiency of the immunodepletion was examined by western blot-
ting the supernatants with antibodies against LSD1 or MTA2.Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc. 663
2008). In order to map the interaction interface of LSD1 with the
members of the MTA family, GST pull-down assays were per-
formed with a GST-fused LSD1 N-terminal fragment (1-166
aa), the SWIRM domain (167-260 aa), and the Tower domain
(419-520 aa) and with in vitro transcribed/translated MTA1,
MTA2, or MTA3. The results indicated that the Tower domain
is responsible for the interaction of LSD1 with MTA1, MTA2, or
MTA3 (Figure 4B). Analogously, mapping the interaction inter-
face in MTAs with GST-fused MTA domain-constructs and
in vitro transcribed/translated LSD1 revealed that the SANT
(Swi3-Ada2-N-CoR-TFIIIB) domain of the MTA proteins is
responsible for the interaction of MTAs with LSD1 (Figure 4C).
It has been reported that bacterially purified LSD1 can deme-
thylate mono- or dimethylated H3K4 only when the substrate is
either a histone peptide or free histone; recombinant LSD1 was
unable to demethylate nucleosomal substrates (Shi et al.,
2004, 2005). It has also been demonstrated that nucleosomal
substrate recognition by LSD1 requires proteins like CoREST
(Shi et al., 2005) that possess a histone-tail-presenting module,
such as the SANT domain, to bridge LSD1 to the chromatin
structure. The interaction of LSD1 with the MTA proteins and
the presence of the SANT domain in these proteins suggest
that the MTA proteins may act as bridging factors in the NuRD
complex for LSD1 to act on nucleosomes. In order to investigate
this hypothesis, we performed histone demethylation assays
on isolated mononucleosomes. As shown in Figure 4D, while
Figure 4. Molecular Interaction between LSD1
and the NuRD Complex
(A) GST pull-down experiments with bacterially
expressed GST-LSD1 and the in vitro transcribed/
translated indicated proteins.
(B) Mapping the interface in LSD1 for the interaction
between LSD1 and MTAs by GST pull-down experi-
ments with GST-fused LSD1 domain-constructs and
in vitro transcribed/translated MTA1, MTA2, or MTA3.
(C) Mapping the interface in MTAs for the interaction
between MTAs and LSD1 by GST pull-down experi-
ments with GST-fused MTA domain-constructs and
in vitro transcribed/translated LSD1.
(D) Requirement for MTA2 in the demethylation of
nucleosomal substrate by LSD1. Mononucleosomes
isolated from HeLa cells were used for demethylation
reactions by His-LSD1 in the presence or absence of
recombinant MTA2.
recombinant LSD1 alone was unable to de-
methylate H3K4, addition of MTA2 to the
demethylation reaction endowed the ability
of recombinant LSD1 to demethylate nucleo-
somal substrates, supporting the idea that
the MTA proteins in the NuRD complex
function to bridge LSD1 to the chromatin
structure.
Transcription Target Analysis for
LSD1/NuRD Complexes
As mentioned earlier, both LSD1 and the
NuRD complex are mainly implicated in
gene transcription repression through their catalytic activities
impacting the chromatin configuration. In order to further inves-
tigate the functional association between LSD1 and the NuRD
complex and to explore the biological significance of this asso-
ciation, we analyzed the genome-wide transcriptional targets
of the LSD1/NuRD complexes using the Chromatin ImmunoPre-
cipitation-DNA Selection and Ligation (ChIP-DSL) approach. It is
believed that the individual members of the MTA family consti-
tute distinct forms of the NuRD complex (Bowen et al., 2004;
Denslow and Wade, 2007). Given our observation that LSD1 is
capable of interacting with all three members of the MTA family,
we designed the ChIP-DSL experiments based on the assump-
tion that LSD1/NuRD complexes include LSD1/MTA1/NuRD,
LSD1/MTA2/NuRD, and LSD1/MTA3/NuRD complexes. In these
experiments, ChIP experiments were conducted in MCF-7 cells
with antibodies against LSD1, MTA1, MTA2, or MTA3. Following
ChIP, LSD1- and MTA-associated DNAs were amplified using
nonbiased conditions, labeled, and hybridized to AVIVA Hu20K
arrays. Relative confidence prediction scores were generated
by quantile normalization across each probe followed by an anal-
ysis using a two-state Hidden Markov model (Mukherjee and
Mitra, 2005). These scores included both probe intensity and
width of probe cluster. Triplicate experiments were performed
to eliminate stochastic false positives, after which peaks that
reproducibly appeared at least twice in the three replicates
were included. The data from LSD1 antibodies were then664 Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc.
analyzed with the data from antibodies against each individual
MTA protein for overlapping promoters, and these promoters
were considered to be the targets of the LSD1/MTA1/
NuRD, LSD1/MTA2/NuRD, and LSD1/MTA3/NuRD complexes
(Figure 5A). Collectively, all targets were considered to be targets
of the LSD1/NuRD complexes. These experiments identified
a total of 1,153 different promoters targeted by the LSD1/
NuRD complexes. Of these, 725 were targeted by the LSD1/
MTA1/NuRD complex, 716 by the LSD1/MTA2/NuRD complex,
and 631 by the LSD1/MTA3/NuRD complex (Figure 5A). Among
them, 252 promoters were identified as common targets for
LSD1/MTA1/NuRD, LSD1/MTA2/NuRD, and LSD1/MTA3/
NuRD. These data indicate that different LSD1/MTA/NuRD
complexes target distinct yet overlapping sets of genes. The
detailed results of the ChIP-DSL experiments are deposited in
GEO Datasets (accession ID: GSE14260) and summarized in
the Supplemental Data Excel spreadsheet.
The genes that are regulated by these promoters were then
classified into cellular signaling pathways for each individual
LSD1/MTA/NuRD complex as well as for all three complexes
combined using MAS software (http://bioinfo.capitalbio.com/
mas) with a p value cutoff of 103. These analyses revealed again
that different LSD1/MTA/NuRD complexes target distinct yet
overlapping signaling pathways (Figure 5A, red rectangles).
Interestingly, analysis of the combined targets of the LSD1/
MTA1/NuRD, LSD1/MTA2/NuRD, and LSD1/MTA3/NuRD com-
plexes identified signaling pathways including TGFb, cell
communication, focal adhesion, MAPK, and cell cycle that are
critically involved in cell growth, survival, migration, and invasion.
The genes in these pathways include, among others, TGFB1,
EGFR, RHOA, ANGPTL4, LAMININ ALPHA 4, COLLAGEN VI
and ENDOTHELIN-1 that are known to be implicated in epithe-
lial-to-mesenchymal transition and/or metastasis.
Real-time quantitative RT-PCR analysis in MCF-7 cells under
LSD1 knockdown of the mRNA expression of selected genes,
including TGFB1, LMNB2, IGF1R, EGFR, CCND1, ADK,
PSEN1, RHOA, FGF21, and APAF1, which represent each of
the pathways, confirmed the ChIP-DSL experiments (Figure 5B,
upper panel). Moreover, in LSD1-overexpressing MCF-7 cells,
knocking down the expression of MTA1 but not MTA2 or MTA3
rendered the lost repression of IGF1R, which was identified as
a target of the LSD1/MTA1/NuRD complex in ChIP-DSL experi-
ments, and knocking down the expression of MTA2 but not
MTA1 or MTA3 led to a relieved repression of RHOA, which
was identified as a target of the LSD1/MTA2/NuRD complex in
ChIP-DSL experiments (Figure 5B, lower panel). These observa-
tions further validated the results from theChIP-DSLexperiments
and support the idea that LSD1 forms distinct NuRD complexes.
The ChIP-DSL experiments were further substantiated by
conventional ChIP to demonstrate that LSD1 and MTA3
co-occupy the TGFB1 promoter in MCF-7 cells (Figure 5C). In
addition, sequential ChIP or ChIP/Re-ChIP (Shang et al., 2000;
Zhang et al., 2004) confirmed that LSD1, MTA3, and Mi-2 exist
in the same protein complex on the TGFB1 promoter (Figure 5C).
Taken together, these experiments not only support the idea that
TGFB1 is targeted by the LSD1/MTA3/NuRD complex but also
confirm that LSD1 is physically associated with and is an integral
component of the NuRD complex in vivo.LSD1 Inhibits Breast Cancer Cell Invasion In Vitro
The identification of the key regulators in epithelial-to-mesen-
chymal transitions, such as TGFb1 (Yang and Weinberg, 2008;
Zavadil and Bottinger, 2005), as targets of LSD1/NuRD
complexes and the well-documented roles of TGFb1 in breast
cancer metastasis (Massague, 2008; Massague et al., 2000;
Padua et al., 2008; Welch et al., 1990; Yang et al., 2008) suggest
that LSD1 may also function in breast cancer invasion and
metastasis. Therefore, we first investigated the effect of LSD1
on the cellular behavior of breast cancer cells in vitro. For this
purpose, LSD1 was overexpressed or knocked down in MDA-
MB-231 cells via lentiviral infection, and the impact of the gain-
of-function and loss-of-function of LSD1 on the invasive
potential of these cells was investigated using transwell invasion
assays. These experiments show that while overexpression of
wild-type LSD1 resulted in more than 3-fold decrease in cell
invasion, overexpression of the Tower domain-deleted LSD1
mutant had little effect on cell invasion (Figure 6A). This is consis-
tent with our observation that LSD1 is incorporated into the
NuRD complex through its interaction with this domain with
MTA proteins. On the other hand, LSD1 knockdown led to
increased cell invasion about 5-fold (Figure 6A). In addition, the
effect of LSD1 on the invasive potential of MDA-MB-231 cells
was probably through the association of LSD1 with the NuRD
complex, as overexpression of LSD1 but knockdown of the
expression of Mi-2 resulted in a diminished LSD1 effect (Fig-
ure 6A). Moreover, the inhibitory effect of LSD1 overexpression
on the invasive potential of MDA-MB-231 cells could be rescued
by addition of exogenous TGFb1 (Figure 6B) and the invasion-
promoting effect of LSD1 knockdown could be effectively
inhibited by SB-431542, an ATP analog inhibitor of the TGFb
type I receptor kinase (Laping et al., 2002) (Figure 6C). The acti-
vation of the TGFb1 signaling by exogenous TGFb1 and inhibi-
tion of the TGFb1 signaling by SB-431542 in MDA-MB-231 cells
were examined by western blotting analysis of the phosphoryla-
tion of SMAD3 and the expression of fibronectin (Figures 6B
and 6C, right panels). These results suggest a critical role of
the TGFb1 signaling pathway in mediating the effect of LSD1
on the invasive potential of MDA-MB-231 cells.
LSD1 Suppresses Breast Cancer Metastatic Potential
In Vivo
In order to further study the invasion-inhibitory effect of LSD1
and to investigate its possible role in breast cancer metastasis
in vivo, MDA-MB-231 cells that had been engineered to stably
express firefly luciferase (MDA-MB-231-Luc-D3H2LN, Xenogen
Corporation) were infected with lentivirues carrying LSD1 cDNA
or LSD1-specific siRNA. The effect of the gain-of-function and
loss-of-function of LSD1 on spontaneous lung metastasis, on
seeding lung metastasis, and on seeding bone metastasis of
MDA-MB-231-Luc-D3H2LN tumors was assessed in immuno-
compromised SCIDmice by orthotopic implantation, intravenous
injection, and intracardiac injection, respectively. In these exper-
iments, MDA-MB-231-Luc-D3H2LN cells were either implanted
into the abdominal mammary fat pad (n = 10), or injected into
the lateral tail vein (n = 8) or the left ventricle (n = 8) of 6-week
old female SCID mice. The growth/dissemination of tumors was
monitoredweekly by bioluminescence imaging with IVIS imagingCell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc. 665
Figure 5. Transcription Target Analysis for LSD1/NuRD Complexes
(A) The experimental scheme and the working model for the ChIP-DSL experiments for the identification of transcriptional targets for LSD1/NuRD complexes in
MCF-7 cells. The numbers represent the number of the promoters that were targeted by the indicated proteins and that appeared at least twice in triplicate exper-
iments. The genes that are regulated by the identified promoters were classified into cellular signaling pathwayswithMAS software (http://bioinfo.capitalbio.com/
mas) with a p value less than 103 and are highlighted with red color. The numbers in the red rectangles represent the number of corresponding pathway-related
genes. The detailed results of the ChIP-DSL experiments are provided in the Supplemental Data Excel spreadsheet.666 Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc.
system (Xenogen Corporation). Tumormetastasis wasmeasured
by quantitative bioluminescence imaging after 7 weeks for ortho-
topically implanted groups. For intravenous injection groups or
the intracardiac injection groups, the quantitative biolumines-
cence imaging was performed at 6 weeks or 4 weeks, respec-
tively, after injection. We defined a metastatic event as any
detectable luciferase signal above background and away from
the primary tumor site. The results showed that, in orthotopically
implanted groups, while either LSD1 overexpression or knock-
downdidnotaffect theability ofMDA-MB-231-Luc-D3H2LNcells
to grow as mammary tumors and to pass into the circulation, the
spontaneous lungmetastasiswassuppressed inanimalscarrying
MDA-MB-231-Luc-D3H2LN tumors with LSD1 overexpression
and was enhanced in animals carrying MDA-MB-231-Luc-
D3H2LN tumorswith LSD1 knockdown, asmeasured by biolumi-
nescence imaging quantifying the photon flux (Figure 7A). In the
intravenous injection groups, significant decreases in lung
metastasis of tumor cells were observed in animals injected
withMDA-MB-231-Luc-D3H2LN cells with LSD1 overexpression
and significant increases in lung metastasis of tumor cells were
recorded in animals injected with MDA-MB-231-Luc-D3H2LN
cells with LSD1 knockdown (Figure 7B). Similarly, the bone
metastasis seeding of tumor cells was significantly decreased
when LSD1 was overexpressed and was greatly enhanced when
LSD1 was knocked down in the intracardiac injection groups
(Figure 7C). The metastases to lung and bone were verified by
histological staining/immunostaining and X-ray examination,
respectively. These experiments indicate that LSD1 overexpres-
sion suppressed the metastatic spread of MDA-MB-231-Luc-
D3H2LN tumors and LSD1 knockdown enhanced the metastatic
spread of the tumors in SCID mice, suggesting that LSD1
suppresses the metastatic potential of breast cancer in vivo.
LSD1 Is Downregulated in Breast Carcinomas and Its
Level of Expression Is Negatively Correlated with that
of TGFB1
In order to further support the role of LSD1 in breast cancer as
well as to substantiate the functional link between LSD1 and
TGFb1 and extend the physiological relevance of this link, we
collected 65 breast tumor samples, of which 30 included adja-
cent normal tissue, from breast cancer patients. The expression
of LSD1 and TGFB1 mRNAs was analyzed by real time RT-PCR
with GAPDH as the internal control. The results revealed a
statistically significant decrease in LSD1 expression in tumors
compared to the adjacent normal mammary tissue (two-tailed
paired t test, n = 30, p = 0.0002). In addition, statistical analysis
found a Spearman correlation coefficient of0.5535 (p < 0.0001)
and a Pearson correlation coefficient of 0.5335 (p < 0.0001)
when the relative level of TGFB1expression was plotted against
the relative level of LSD1 expression in breast carcinoma
samples (n = 65), indicating a significant negative correlation
between LSD1 and TGFB1 expression in these samples. Thesedata are consistent with a role of LSD1 in suppressing breast
cancer metastasis and support TGFb1 as a downstream effector
of LSD1.
DISCUSSION
Both LSD1 and the NuRD complex primarily function in tran-
scription repression programs by virtue of their enzymatic
activities and through their chromatin remodeling capabilities.
Specifically, LSD1 targets H3-K4 for demethylation and the
NuRD complex possesses histone deacetylation activity. As
both demethylation and deacetylation are essential epigenetic
mechanisms in controlling gene transcription, interplay between
deacetylation and demethylation is a logical scenario. Indeed,
past studies have indicated that histone deacetylation and
demethylation are interdependent (Denslow and Wade, 2007;
Lee et al., 2006; Shi et al., 2005). We propose that LSD1 is an
integral component of the NuRD complex, placing deacetylase
and demethylase activities into the same protein complex. By
enlisting LSD1, the NuRD complex arsenal would include
ATPase, deacetylase, and demethylase. The question then is:
what is the biological significance of having all of these enzy-
matic activities in one single assembly? As stated above, these
enzymatic activities are part of the whole pact of epigenetic
actions that are necessary to bring a gene to a silenced state.
Therefore, it is conceivable that evolution favors a physical prox-
imity for more efficient functional interaction of distinct enzy-
matic activities. Such a stoichiometry would benefit for an exqui-
site coordination of distinct chromatin remodeling activities in
finely-tuned gene regulation. In fact, in addition to these chro-
matin modification capacities, the NuRD complex also contains
MBD2/MBD3, a protein that is connected to DNA methylation,
another epigenetic mechanism in gene regulation. It is not
expected that the NuRD complex contains all types of epigenetic
modifiers, but it will not be surprising if future investigations
uncover additional enzymatic activities that are associated
with this complex, especially considering the dynamic nature
of the assembly and functioning of this complex. In addition,
as H3-K4 methylation encodes for a well-recognized epigenetic
message signaling gene activation, it is logical to imagine that
the repression function of the NuRD complex contains an enzy-
matic activity to erase this mark. Moreover, it is believed that at
least one of the mechanistic manifestations for functional spec-
ificity of different forms of the NuRD complex is to be recruited by
different transcription factors. To date, the NuRD complex has
been shown to mediate transcription repression by distinct
sequence-specific transcription factors including p53, Ikaros,
Hunchback, Tramtrack69, KAP-1, BCL-6, and FOG-1 (Denslow
and Wade, 2007). Interestingly, at least some of these transcrip-
tion factors, such as p53, Ikaros, and Tramtrack88, also recruit
LSD1 (Lan et al., 2008), again favoring a model in which LSD1
and the NuRD complex act together. More importantly, evidence(B) Verification of the ChIP-DSL results by real-time RT-PCR analysis of mRNA expression of the indicated genes in MCF-7 cells after transfection with LSD1
expression vector, control siRNA, or siRNAs targeting MTA1, MTA2, or MTA3 as indicated. Each bar represents the mean ± SD for triplicate measurements.
The effect of RNAi on protein expression was examined by western blotting with antibodies against the indicated proteins.
(C) LSD1 and the NuRD complex exist in the same protein complex on the TGFB1 promoter. ChIP and Re-ChIP experiments were performed in MCF-7 cells with
the indicated antibodies.Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc. 667
clearly points to a convergent role of LSD1 and the NuRD
complex in cell fate determination and differentiation (Bowen
et al., 2004; Shi, 2007), supporting a physical association and
thus a functional connection between LSD1 and the NuRD
complex. It is conceivable that LSD1, through being incorpo-
rated into and forming distinct NuRD complexes, is recruited
by distinct pathway-specific transcription factors to exert its
pathway-specific functions.
LSD1 has been implicated in cellular growth pathways and it
has been linked with several types of cancer (Kahl et al., 2006;
Wang et al., 2007a). Our experiments demonstrated, by both
gain-of-function and loss-of-function studies, that LSD1 had
dramatic effects on the metastatic behavior of MDA-MB-231
cells. ChIP-DSL analyses revealed that the LSD1/NuRD com-
plexes target the promoters of an array of genes that constitute
several important cellular signaling pathways pertinent to cell
growth, survival, migration, and invasion. These include the
TGFb signaling pathway that is critically involved in epithelial-
mesenchymal transitions and tumor invasion. Because epithe-
lial-mesenchymal transition and metastasis are such hallmark
events in morphogenesis and cell survival, the connection of
LSD1 with these cellular behaviors emphasizes the importance
of LSD1 in normal physiology and pathobiology. This is under-
scored by the observation that LSD1 ablation causes embryonic
lethality in mice (Wang et al., 2007b). On the other hand, as
important as the epithelial-mesenchymal transition and metas-
tasis are, it is logical to believe that only well-coordinated and
sophisticated molecular machineries would make these
missions possible. The association of LSD1 with the NuRD
complex and the formation of different LSD1/NuRD complexes
may thus provide at least a clue about the role of LSD1 in this
sophisticated coordination. It is reasonable to believe that the
aforementioned cell fate determination and differentiation func-
tion of LSD1 and the NuRD complex are due at least in part to
the concerted networking of different forms of the LSD1/NuRD
complexes. These functions represent the cellular readouts of
the coordinated molecular actions of these complexes in normal
development and in tumor invasion.
Our data indicate that modulating the expression of LSD1 did
not affect the ability of MDA-MB-231 cells to grow as mammary
tumors or to pass into the circulation in animals but did influence
the invasive potential in cell culture. The reason for this discrep-
ancy is not clear. But it is reasonable to expect a certain degree
of difference between the behavior of the cells in vitro and in vivo.
TGFb1 is a key player in epithelial-mesenchymal transitions
and tumor invasion (Dumont and Arteaga, 2003; Massague,
2008;Massague et al., 2000; Siegel andMassague, 2003; Thiery,
2002). In fact, a recent study indicated that TGFb1 could prime
and empower breast cancer cells for metastasis to the lungs
(Padua et al., 2008). Therefore, the regulation of TGFb1 by
Figure 6. LSD1 Inhibits the Invasive Potential of MDA-MB-231 Cells
In Vitro
(A) MDA-MB-231 cells were infected with lentiviruses carrying either empty
vector, LSD1 expression vector, LSD1DTower, control siRNA, or LSD1 siRNA,
or transfected with Mi-2 siRNA as indicated. The cells were starved for 18 h
before cell invasion assays were performed using Matrigel transwell filters.
The invaded cells were stained and counted. The images represent one field
undermicroscopy in control (vector) and LSD1-overexpressing (LSD1) groups,
respectively. Each bar represents the mean ± SD for triplicate measurements.
The protein expression in these experiments was examined by western blot-
ting using antibodies against the indicated proteins.
(B) Exogenous TGFb1 alleviated the invasion-inhibitory effect of LSD1 overex-
pression. Cell invasion assays were performed in MDA-MB-231 cells under
overexpression of LSD1 and the treatment with 100 pM of TGFb1. The invaded
cells were stained and counted. Each bar represents the mean ± SD for tripli-
cate measurements. The activation of TGFb1 signaling pathway in these cells
by exogenous TGFb1was examined bywestern blotting analysis of the level of
phosphorylated SMAD3 (pSMAD3), total SMAD3, and fibronectin, a down-
stream target of the TGFb1 signaling pathway.
(C) Inhibition of TGFb1 signaling by SB-431542 suppressed the invasion-
promoting effect of LSD1 knockdown. Cell invasion assays were performed
in MDA-MB-231 cells under knockdown of LSD1 and treatment with 10 mM of
SB-431542. The invaded cells were stained and counted. Each bar represents
themean±SD for triplicatemeasurements. The inhibition of TGFb1 signaling by
SB-431542 inMDA-MB-231 cellswasconfirmedbywesternblotting analysis of
the level of phosphorylated SMAD3 (pSMAD3), total SMAD3, and fibronectin.668 Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc.
Figure 7. LSD1 Suppresses Breast Cancer Metastatic Potential In Vivo
(A) The effect of LSD1 on spontaneous lung metastasis of orthotopic breast cancer cells. MDA-MB-231-Luc-D3H2LN cells were infected with lentiviruses
carrying either empty vector (vector), LSD1 expression construct (LSD1), control siRNA (control), or LSD1 siRNA, and were inoculated orthotopically into theCell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc. 669
LSD1/NuRDcomplexesmay have significant physiological impli-
cations. In agreement with this notion, we found that LSD1
suppresses breast cancer metastatic potential in vivo. We also
showed that LSD1 expression was significantly lower in tumor
samples compared to adjacent normal tissue and that the level
of LSD1 expression was negatively correlated with the level of
TGFb1 expression. These results support a model in which at
least one of the cellular functions of LSD1 is to incorporate into
the NuRD complex and to target the epithelial-mesenchymal
transition and tumor metastatic programs including the TGFb
signaling pathway. This proposition is consistent with reports
by others that above-mentioned LSD1/NuRD-recruiting tran-
scription factors, such as p53 (Sasai et al., 2008) and Hunchback
(Yamazaki et al., 2006), target TGFb signaling.
It remains to be investigated the functional association of LSD1
with the NuRD complex in normal development and physiology.
Also relevant to our observations, it will be important to determine
the molecular basis underlying differential promoter recognition
by the different forms of the LSD1/NuRD complex and to explore
themechanismbywhich thecoordinatedactionsofdistinct LSD1/
NuRD complexes are achieved in the epithelial-mesenchymal
transition in normal development and to investigate how this coor-
dination might be altered in tumor metastasis. Interestingly, our
experiments identified BRCA2 in LSD1/NuRD complexes. The
significance of this association needs further investigation. Rele-
vant to this, ChIP-DSL identified BRCA2 as a common target of
the LSD1/NuRD complexes; also CHD4 (Mi-2b) was identified
as a target for the LSD1/MTA1/NuRD complex and MTA3 itself
was identified as a target for the LSD1/MTA3/NuRD complex.
Whether feedback regulatory loops exist for the LSD1/NuRD
complexes and what role(s) this mechanism might contribute to
the coordinated actions of different forms of LSD1/NuRD
complexes need tobedetermined.Nevertheless, if our interpreta-
tion is correct, our experiments indicate that LSD1 is a bona fide
subunit of theNuRDcomplex, expanding theenzymatic repertoire
of the NuRD complex in epigenetic regulation and providing
a molecular basis for the interdependence of histone deacetyla-
tion and demethylation in chromatin remodeling. We showed
that LSD1 represses the transcription of a number of important
cellular regulators and suppresses breast cancer metastasis,
supporting the pursuit of LSD1 as a target for cancer therapy.670 Cell 138, 660–672, August 21, 2009 ª2009 Elsevier Inc.EXPERIMENTAL PROCEDURES
Immunopurification and Mass Spectrometry
Lysates from HeLa cells stably expressing FLAG-MTA2 were applied to an
equilibrated FLAG column. The column was then washed and the protein
complex was eluted with FLAG peptides (Sigma). Fractions of the bed volume
were collected and resolved on SDS-PAGE, silver stained, and subjected to
LC-MS/MS sequencing and data analysis.
FPLC Chromatography
HeLa nuclear extracts were applied to a Superose 6 size exclusion column
(Amersham Biosciences) that had been equilibrated with dithiothreitol-con-
taining buffer and calibrated with protein standards (blue dextran, 2000 kDa;
thyroglobulin, 669 kDa; ferritin, 440 kDa; catalase, 232 kDa; bovine serum
albumin, 67 kDa; and RNase A, 13.7 kDa; all from Amersham Biosciences).
The column was eluted at a flow rate of 0.5 ml/min and fractions were
collected.
Demethylation and Deacetylation Assays
Calf thymus bulk histones (Sigma) were incubated with MTA2-containing
complex in histone demethylase assay buffer. The reaction mixture was
analyzed by western blotting against di- or mono-methyl-H3K4, di-methyl-
H3K9, acetyl-H3K9/K14, and H3 N-terminal tail. For radiolabeled demethyla-
tion assays, [3H]methyl-labeled histone substrates were prepared and incu-
bated with the MTA2-containing complex. The radioactivity was measured
by liquid scintillation counting. For radiolabeled deacetylation assays, protein
fractions were incubated with [3H]acetate-labeled HeLa histones that had
been isolated from butyrate-treated HeLa cells. The released [3H]acetate
was extracted with ethyl acetate and quantified by liquid scintillation counting.
Immunoprecipitation and Immunodepletion
For immunoprecipitation assays, cellular extracts were incubated with appro-
priate primary antibodies or normal rabbit/mouse immunoglobin G (IgG) at 4C
overnight, followed by addition of protein A/G Sepharose CL-4B beads for 2 hr
at 4C.Beadswere thenwashed and the immunecomplexeswere subjected to
SDS-PAGE followed by immunoblotting with secondary antibodies. Immuno-
detection was performed using enhanced chemiluminescence (ECL System,
Amersham Biosciences) according to the manufacturer’s instructions. For
immunodepletion assays, preimmune serum or specific antibodies were first
immobilized to protein A/G-Sepharose. HeLa immunoprecipitates were incu-
bated with antibody-conjugated protein A/G-Sepharose beads for 2 hr at 4C.
The precipitates were removed by centrifugation, and the supernatants were
subjected to a second round of immunodepletion with protein A/G-Sepharose
resins freshly preadsorbed with corresponding antibodies. After removing the
resins by centrifugation, the supernatants were transferred to new tubes and
stored at 70C until used.abdominal mammary fat pad of 6-week-old female SCIDmice (n = 10). Tumor size wasmeasured on day 28 (mammary tumors, n = 6). The presence of circulating
tumor cells (intravasation, n = 3) was assessed by real time RT-PCR as a function of human GAPDH expression relative to murine b2-microglobulin in 3 ml of
mouse blood perfusate. Primary tumors and lung metastases were quantified using bioluminescence imaging (n = 5-6) after 7 weeks of initial implantation. Error
bars indicate mean ± SD; *p < 0.002 (two-tailed paired t test). Representative in vivo bioluminescent images are shown.
(B) The effect of LSD1 on seeding lung metastasis of intravenously injected breast cancer cells. The above described MDA-MB-231-Luc-D3H2LN cells were
injected intravenously through the tail vein of 6-week-old female SCIDmice (n = 8). Lung metastasis was quantified using bioluminescence imaging after 6 weeks
(n = 6–8). Error bars indicate mean ± SD; *p < 0.01 (two-tailed paired t test). Lung sections from normal (untreated) or LSD1 siRNA-treated mice were stained with
H&E or were immunostainedwith antibodies specific for humanMTA2 (Abcam, ab9949) (middle). Representative in vivo bioluminescent images are shown (right).
(C) The effect of LSD1 on seeding bone metastasis of intracardiacally injected breast cancer cells. The above described MDA-MB-231-Luc-D3H2LN cells were
injected into the left ventricle of female SCID mice (n = 8). Bone metastasis was quantified after 4 weeks using bioluminescence imaging of the mouse hindlimbs
(n = 6). Error bars indicate mean ± SD; *p < 0.01 (two-tailed paired t test). Representative mouse hindlimb radiographs (middle; white arrows indicate metastases)
from control siRNA (control)- or LSD1 siRNA-treated mice and bioluminescent images (right) are shown.
(D) Confirmation of LSD1 overexpression and knockdown in MDA-MB-231-Luc-D3H2LN cells used in animal experiments by western blotting.
(E) LSD1 is downregulated in breast carcinomas. Paired breast tumor samples versus adjacent normal tissue (n = 30) were analyzed by real time RT-PCR for the
expression of LSD1 mRNA with GAPDH as the reference.
(F) The level of LSD1 mRNA expression in breast carcinomas is negatively correlated with that of TGFB1. The expression of LSD1 and TGFB1 mRNAs was
analyzed by real time RT-PCR in 65 breast carcinoma samples with GAPDH as the reference. The relative level of TGFB1expression was plotted against the
relative level of LSD1 expression.
ChIP-DSL
ChIP samples were amplified by ligation-mediated PCR as described (Kwon
et al., 2007). DNA fragmentation, biotin labeling, and hybridization were per-
formed according to a protocol from Aviva Systems Biology (http://www.
avivasysbio.com) using Aviva Hu20K arrays. Experiments were repeated three
times and the results were analyzed using MAS (http://bioinfo.capitalbio.com/
mas/login.do) with a p value cutoff of 1.0 x106 for promoter identification and
p < 0.001 for pathway analysis.
ChIP and Re-ChIP
ChIP and Re-ChIP were performed in MDA-MB-231 cells as described previ-
ously (Zhang et al., 2006; Zhang et al., 2004; Zhang et al., 2007). The enrich-
ment of the DNA template was analyzed by conventional PCR using primers:
forward: 50-GATGGCACAGTGGTCAAGAGC-30 and reverse: 50-GAAGGATG
GAAGGGTCAGGAG-30 specific for TGFB1 gene promoter.
Lentiviral Production and Infection
Recombinant lentiviruses were constructed by subcloning human LSD1 into
the iDuet101 shuttle vector (Ye et al., 2008). The recombinant construct as
well as two assistant vectors: cytomegalovirus (CMV) R8.91 and pMD.G,
were then transiently transfected into HEK293T cells. Viral supernatants
were collected, filtered, concentrated, and used to infect cells. The construc-
tion of RNAi lentivirus system using pLL3.7 and other LentiLox vectors was
carried out according to a protocol described online (http://web.mit.edu/
jacks-lab/protocols/lentiviralproduction.htm). In brief, siRNA sequences tar-
geting LSD1 were designed and cloned into the pLL3.7 shuttle vector. The
recombinant construct, as well as three assistant vectors: pMDLg/pRRE,
pRSV-REV, and pVSUG, were then transiently transfected into HEK293T cells.
Viral supernatants were collected 48 h later, clarified by filtration, and concen-
trated by ultracentrifugation. The concentrated virus was used to infect 53 105
cells in a 60mmdish with 8 mg/ml polybrene. InfectedMDA-MB-231 cells were
then subjected to sorting by EGFP expression.
Cell Invasion Assay
Transwell chamber filters (Chemicon Incorporation) were coated withMatrigel.
After infection with lentivirus, MDA-MB-231 cells were starved for 18 hr in
DMEM containing 0.1%BSA, and 1.53 105 of cells in 300 ml serum free media
were placed to the upper chamber of the transwell. The chamber was then
transferred to a well containing 500 ml of media containing 10% fetal bovine
serum. Cells were incubated for 24 hr at 37C. Cells in the top well were
removed by wiping the top of the membrane with cotton swabs. The
membranes were then stained and the remaining cells were counted. Five
high-powered fields were counted for each membrane.
In vivo Metastasis
MDA-MB-231 cells that hadbeenengineered to stably express firefly luciferase
(MDA-MB-231-Luc-D3H2LN) (XenogenCorporation)were infectedwith lentivi-
ruses carrying empty vector, LSD1 expression construct, control siRNA, or
LSD1 siRNA. These cells were inoculated into the left abdominal mammary
fat pad (2 3 106 cells) or injected into the lateral tail vein (1 3 106 cells) or the
left ventricle (1 3 105 cells) of 6-week-old female SCID mice. For biolumines-
cence imaging, mice were anesthetized and given 150 mg/g of D-luciferin in
PBS by i.p. injection. Fifteen minutes after injection, bioluminescence was
imaged with a charge-coupled device camera (IVIS; Xenogen). Biolumines-
cence images were obtained with a 15 cm field of view, binning (resolution)
factor of 8, 1/f stop, open filter, and an imaging time of 30 s to 2 min. Biolumi-
nescence from relative optical intensity was defined manually, and data were
expressed as photon flux (photons$sec1$cm2$steradian1) and were
normalized tobackgroundphoton fluxwhichwasdefined froma relative optical
intensity drawn over a mouse that was not given an injection of luciferin. The
difference in animal numbers (n) in relevant groups was due to the animal
loss during the experiments. Animal handling and procedures were approved
by the Peking University Health Science Center Institutional Animal Care and
Use Committee.Statistical Analysis
Results are reported as mean ± SD. Comparisons were performed using two-
tailed paired t test.
Detailed information about the materials and methods can be found in the
Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Results, Supplemental References,
and an Excel spreadsheet and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)00710-7.
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